" class="no-js "lang="en-US"> Needle-Free Delivery Boosts Immune Response of DNA Vaccines
Wednesday, May 15, 2024

Needle-Free Precision Delivery Systems Boost Immune Response of DNA Vaccines: Comprehensive Scientific Literature Review

Results of a comprehensive review of published scientific literature comparing data associated with various DNA vaccines delivery methods will be presented at the World Vaccine Congress 2023 on April 5, 2023 at 5:10 pm ET. The presentation will be the first such in-depth comparison and public discussion of existing DNA vaccine administration modalities and their inherent benefits and challenges in the COVID-19 era.

Titled, Improved vaccine uptake and clinical responses with Needle-Free PharmaJet Precision Delivery Systems, the presentation will discuss the safety, immunogenicity and clinical efficacy of DNA vaccines when administered using needle-free precision delivery systems (PDS) and alternative methods including electroporation, gene gun, and needle and syringe (N/S) delivery.

Topline results of the analysis showed that DNA vaccines delivered needle-free tend to induce immunogenicity that is non-inferior to electroporation. DNA vaccines delivered needle-free also tend to elicit improved immunogenicity compared with N/S, according to the authors of the publication. In addition, compared with electroporation and with N/S, needle-free PDS provide a wider dispersion pattern of the DNA vaccine within tissues and more precise, efficient delivery into cells.

“When it comes to administering vaccines, two of the most important clinical outcomes are increased immunogenicity and enhanced protection from disease,” said Erin Spiegel, Ph.D, Vice President Clinical and Regulatory Affairs, PharmaJet. “This comprehensive scientific review clearly shows that needle-free delivery of DNA vaccines can accomplish both outcomes, outperforming alternative methods. The data associated with needle-free precision delivery systems demonstrate this technology platform can be expected to enhance vaccine immune response.” She added, “We are committed to continue investigating the benefits of our precision delivery systems when combined with DNA or other vaccine platforms.”

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more